<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nephrol Dial Transplant</journal-id><journal-id journal-id-type="iso-abbrev">Nephrol. Dial. Transplant</journal-id><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-id journal-id-type="hwp">ndt</journal-id><journal-title-group><journal-title>Nephrology Dialysis Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0931-0509</issn><issn pub-type="epub">1460-2385</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23787550</article-id><article-id pub-id-type="pmc">3769980</article-id><article-id pub-id-type="doi">10.1093/ndt/gft203</article-id><article-id pub-id-type="publisher-id">gft203</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject><subj-group subj-group-type="heading"><subject>Intra- and Extracorporeal Treatments of Kidney Failure</subject></subj-group></subj-group></article-categories><title-group><article-title>A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: <italic>post hoc</italic> evaluation from a controlled, randomized study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Covic</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="gft203_af1">1</xref><xref ref-type="corresp" rid="gft203_cor1"/></contrib><contrib contrib-type="author"><name><surname>Passlick-Deetjen</surname><given-names>Jutta</given-names></name><xref ref-type="aff" rid="gft203_af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kroczak</surname><given-names>Miroslaw</given-names></name><xref ref-type="aff" rid="gft203_af3">3</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000fc;schges-Seraphin</surname><given-names>Beatrix</given-names></name><xref ref-type="aff" rid="gft203_af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ghenu</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="gft203_af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ponce</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="gft203_af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Marzell</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="gft203_af7">7</xref></contrib><contrib contrib-type="author"><name><surname>de Francisco</surname><given-names>Angel L.M.</given-names></name><xref ref-type="aff" rid="gft203_af8">8</xref></contrib></contrib-group><aff id="gft203_af1"><label>1</label><addr-line>Clinic of Nephrology</addr-line>, <institution>C. I. Parhon University Hospital, Gr T. Popa; University of Medicine and Pharmacy</institution>, <addr-line>IASI</addr-line>, <country>Romania</country></aff><aff id="gft203_af2"><label>2</label><addr-line>Nephrology</addr-line>, <institution>Heinrich-Heine University</institution>, <addr-line>D&#x000fc;sseldorf</addr-line>, <country>Germany</country></aff><aff id="gft203_af3"><label>3</label><institution>Fresenius NephroCare</institution>, <addr-line>Sieradz</addr-line>, <country>Poland</country></aff><aff id="gft203_af4"><label>4</label><institution>KfH Kuratorium f&#x000fc;r H&#x000e4;modialyse</institution>, <addr-line>F&#x000fc;rth</addr-line>, <country>Germany</country></aff><aff id="gft203_af5"><label>5</label><institution>County Hospital Targoviste</institution>, <addr-line>Targoviste</addr-line>, <country>Romania</country></aff><aff id="gft203_af6"><label>6</label><institution>Almada-NMC-Centro M&#x000e9;dico Nacional</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff><aff id="gft203_af7"><label>7</label><institution>Fresenius Medical Care</institution>, <addr-line>Bad Homburg</addr-line>, <country>Germany</country></aff><aff id="gft203_af8"><label>8</label><institution>Universidad de Cantabria</institution>, <addr-line>Santander</addr-line>, <country>Spain</country></aff><author-notes><corresp id="gft203_cor1"><italic><italic>Correspondence and offprint requests to:</italic></italic> Adrian Covic; E-mail: <email>adriancovic@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>6</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>28</volume><issue>9</issue><fpage>2383</fpage><lpage>2392</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.</copyright-statement><copyright-year>2013</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="gft203.pdf"/><abstract><sec><title>Background</title><p>Different phosphate binders exert differing effects on bone mineral metabolism and levels of regulating hormones. The objective of this <italic>post hoc</italic> evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects of calcium acetate/magnesium carbonate (CaMg) and a calcium-free phosphate binder, sevelamer-hydrochloride (HCl), on serum levels of fibroblast growth factor-23 (FGF-23) and markers of bone turnover.</p></sec><sec><title>Methods</title><p>This secondary analysis of the controlled, randomized CALMAG study, comparing the effect of CaMg and sevelamer-HCl on serum phosphorus (P), aimed to investigate the parameters described above. The analysis included 204 patients who completed the initial study per protocol (CaMg, <italic>n</italic> = 105; sevelamer-HCl, <italic>n</italic> = 99).</p></sec><sec><title>Results</title><p>The study showed that serum levels of FGF-23 were significantly reduced with CaMg and sevelamer-HCl, with no difference between groups at Week 25 [analysis of covariance (ANCOVA); log-intact FGF-23 (iFGF-23), P = 0.1573]. FGF-23 levels strongly correlated with serum P levels at all time points in both groups. The bone turnover parameters alkaline phosphatase (AP), bone AP (BAP), procollagen type 1 amino-terminal propeptide 1 (P1NP), osteoprotegerin (OPG), beta-crosslaps (&#x003b2;-CTX) and tartrate-resistant acid phosphatase 5b (TRAP 5b) increased significantly in the sevelamer-HCl group; they remained almost unchanged in the CaMg group, after the initial phase of P lowering (ANCOVA, P &#x0003c; 0.0001 for all except OPG, P = 0.1718).</p></sec><sec><title>Conclusions</title><p>CaMg and sevelamer-HCl comparably lower serum levels of iFGF-23. Changes in bone parameters were dependent on characteristics of the phosphate binder; in contrast with sevelamer-HCl, CaMg had no influence on bone turnover markers.</p></sec></abstract><kwd-group><kwd>bone markers</kwd><kwd>calcium acetate</kwd><kwd>fibroblast growth factor-23</kwd><kwd>haemodialysis</kwd><kwd>magnesium carbonate</kwd><kwd>phosphate binder</kwd></kwd-group></article-meta></front><body><sec id="gft203_s1"><title>INTRODUCTION</title><p>In patients with chronic kidney disease stage 5 (CKD 5), elevated serum phosphorus (P) levels are associated with an increased risk of morbidity and mortality [<xref ref-type="bibr" rid="GFT203C1">1</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C6">6</xref>]. Therefore, control of serum P levels is a key objective in the management of chronic kidney disease-mineral and bone disorder (CKD&#x02013;MBD). In addition to optimal dialysis and dietary restrictions, oral phosphate binders such as calcium (Ca) acetate and the non-Ca-containing agent sevelamer-hydrochloride (HCl) constitute key treatment options in hyperphosphataemia. The recent CALcium acetate MAGnesium carbonate (CALMAG) randomized, controlled trial demonstrated that the combination phosphate binder calcium acetate/magnesium carbonate (CaMg) is non-inferior to sevelamer-HCl at controlling serum P levels in patients receiving haemodialysis (HD), thus, presenting another effective treatment option [<xref ref-type="bibr" rid="GFT203C7">7</xref>].</p><p>Hyperphosphataemia is associated with elevated levels of fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH) [<xref ref-type="bibr" rid="GFT203C8">8</xref>]. Increased FGF-23, hyperphosphataemia and elevated PTH are independently associated with increased mortality in CKD [<xref ref-type="bibr" rid="GFT203C9">9</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C14">14</xref>]. FGF-23, a master regulator of P, PTH and 1,25-(OH)<sub>2</sub>D<sub>3</sub> [<xref ref-type="bibr" rid="GFT203C15">15</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C17">17</xref>], is also implicated in cardiovascular disease [<xref ref-type="bibr" rid="GFT203C10">10</xref>, <xref ref-type="bibr" rid="GFT203C14">14</xref>, <xref ref-type="bibr" rid="GFT203C18">18</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C20">20</xref>] and is becoming increasingly recognized as an important marker for outcome and severity of disease in CKD&#x02013;MBD. However, unfortunately there are currently very few strategies available to enable a significant reduction in its level in patients with CKD.</p><p>Recent studies have reported a greater reduction in FGF-23 with sevelamer-HCl than with Ca acetate [<xref ref-type="bibr" rid="GFT203C21">21</xref>, <xref ref-type="bibr" rid="GFT203C22">22</xref>] and, therefore, there is now an increased interest in investigating how other, newer phosphate-binding agents (such as CaMg) affect FGF-23. Previous studies that have investigated the impact of phosphate binders on bone metabolism include the comparison between sevelamer-HCl and Ca acetate [<xref ref-type="bibr" rid="GFT203C21">21</xref>] and between sevelamer-HCl and Ca carbonate [<xref ref-type="bibr" rid="GFT203C23">23</xref>]; however, no comparisons of sevelamer-HCl and CaMg have yet been reported. Moreover, as an emerging role of FGF-23 in the bone&#x02013;kidney axis becomes apparent [<xref ref-type="bibr" rid="GFT203C24">24</xref>], it is also important to compare the concomitant changes in bone markers in response to treatment.</p><p>In order to evaluate the effects of different phosphate binders on FGF-23 and markers of bone turnover, we performed a secondary analysis of data from the CALMAG study comparing the effect of CaMg versus sevelamer-HCl on these parameters in patients receiving HD.</p></sec><sec sec-type="methods" id="gft203_s2"><title>SUBJECTS AND METHODS</title><sec id="gft203_s2a"><title>Study population and design</title><p>Full details of the CALMAG study, which compared the tolerability and efficacy of two different oral phosphate binder treatments (CaMg and sevelamer-HCl) for 24 weeks in HD or online haemodiafiltration (HDF) patients, have been described previously [<xref ref-type="bibr" rid="GFT203C7">7</xref>]. The primary endpoint of the original trial was to determine the efficacy of CaMg compared with sevelamer-HCl as an active control in lowering serum P [<xref ref-type="bibr" rid="GFT203C7">7</xref>].</p><p>This secondary analysis was performed with the objective of comparing the effects of both phosphate binders on FGF-23 and different bone turnover markers.</p><p>Patients aged 18&#x02013;85 years, in stable condition, without additional serious illness, received one of two study medications: 435 mg of Ca acetate (containing 110 mg elemental Ca) combined with 235 mg of magnesium (Mg) carbonate (containing 60 mg elemental Mg) (OsvaRen&#x000ae;; Fresenius Medical Care Nephrologica Deutschland GmbH, Bad Homburg, Germany) or sevelamer-HCl 800 mg (Renagel&#x000ae;; Genzyme Corporation, Cambridge, MA) for 24 weeks. A standardized titration scheme was used in order to reduce serum P levels &#x0003c;1.78 mmol/L (5.5 mg/dL).</p></sec><sec id="gft203_s2b"><title>Study parameters</title><p>In addition to parameters reported previously, serum samples from baseline, Weeks 9 and 25 were also analysed for FGF-23. Markers of bone formation including alkaline phosphatase (AP), bone AP (BAP), procollagen type 1 amino-terminal propeptide 1 (P1NP) and osteoprotegerin (OPG) were determined as well as a marker of bone resorption, beta-crosslaps (&#x003b2;-CTx), and a marker of osteoclast activity, tartrate-resistant acid phosphatase 5b (TRAP 5b).</p><p>Measurements were performed at the central laboratory using the following assays: inorganic P, molybdate reaction without deproteinization; total Ca, photometric colour test; ionized Ca (iCa), OPTI&#x000ae; R blood gas analysis (OPTI Medical); total Mg, xylidyl blue; intact PTH (iPTH), human intact PTH electrochemiluminescence immune assay (ECLIA); intact FGF-23 (iFGF-23), human intact FGF-23 enzyme-linked immunosorbent assay (ELISA) (Immutopics); AP, according to International Federation of Clinical Chemistry and Laboratory Medicine, 37&#x000b0;C; BAP and TRAP 5b, enzyme immunoassay (EIA) (Microvue Bonehealth, Quidel Corporation, Biosource); &#x003b2;-CTX and P1NP, ECLIA for Cobas/Elecsys (Roche); human OPG, ELISA (Biovendor).</p><p>Reference values: P, 0.87&#x02013;1.45 mmol/L; total Ca, 2.20&#x02013;2.60 mmol/L; iCa, 0.95&#x02013;1.35 mmol/L; total Mg, 0.65&#x02013;1.05 mmol/L; iPTH, 15&#x02013;65 pg/mL; iFGF-23, 7.0&#x02013;29.3 pg/mL; AP, female 35&#x02013;104 U/L, male 40&#x02013;129 U/L; BAP, female median 25.0 U/L (90% CI 14.2&#x02013;42.7 U/L), male median 23.2 U/L (90% CI 15.0&#x02013;41.3 U/L); P1NP, female median 37.09 &#x000b5;g/L (5&#x02013;95th percentile, 16.27&#x02013;73.87 &#x000b5;g/L); &#x003b2;-CTx, female 556 &#x000b1; 226 pg/mL, male 304 &#x000b1; 200 pg/mL; TRAP 5b, female 4.3 &#x000b1; 1.5 U/L, male 4.0 &#x000b1; 1.4 U/L; OPG, mean 4.1 &#x000b1; 2.3 pmol/L.</p></sec><sec id="gft203_s2c"><title>Statistical analysis</title><p>The differences in biochemical serum parameters between treatment groups were tested using an analysis of covariance (ANCOVA) model for repeated measures. The factors for study treatment, centre (pooled), dialysate Ca concentration, dialysis method (HD or online-HDF) and use of vitamin D and cinacalcet were included in the model. The respective baseline value was added as a covariate.</p><p>Differences between groups in mean baseline biochemical serum parameters were tested using the Mann&#x02013;Whitney test. Wilcoxon tests were applied to describe the statistical significance of changes over time within a treatment group. All tests were carried out at a two-sided significance level <italic>&#x003b1;</italic> of 5%.</p><p>In order to dissect the acute effect of phosphate lowering after the wash-out and the long-term effect of different phosphate binders, in addition to the overall comparison, we split the analysis into two phases: the initial phase of phosphate lowering, Weeks 1&#x02013;9, and the maintenance phase, Weeks 9&#x02013;25.</p><p>All analyses were based on the per protocol set (PPS), which included all patients who were randomized and completed the study without major protocol violations. Data and figures are presented as median and interquartile range (Q3&#x02013;Q1). Pearson's correlation coefficients <italic>and the respective two-sided P values</italic> were calculated between iFGF-23, iPTH, actual bicarbonate and P, iCa, total Ca, Mg, AP, BAP, P1NP, OPG, TRAP 5b and &#x003b2;-CTx over the whole treatment period and at all measured time points.</p></sec></sec><sec sec-type="results" id="gft203_s3"><title>RESULTS</title><sec id="gft203_s3a"><title>Patients and baseline characteristics</title><p>Of the 326 patients who were included in the CALMAG study, 255 were randomized and 204 [105 patients (CaMg) and 99 patients (sevelamer-HCl)] completed the study as per protocol. There were no significant differences in baseline characteristics between groups in terms of underlying disease, comorbidities or disposition of covariates, including the use of any vitamin D (reported previously) [<xref ref-type="bibr" rid="GFT203C7">7</xref>] or in biochemical serum parameters (Table&#x000a0;<xref ref-type="table" rid="GFT203TB1">1</xref>). In both of the groups, the minority of patients (CaMg: 38.1%, <italic>n</italic> = 40; sevelamer-HCl: 29.3%, <italic>n</italic> = 29) were treated with any form of vitamin D, either with cholecalciferol, calcitriol or another vitamin D receptor activator. As written in the protocol and as confirmed by further analysis of co-medication, baseline medication was not changed during the course of the study.<table-wrap id="GFT203TB1" position="float"><label>Table&#x000a0;1.</label><caption><p>Baseline biochemical serum parameters (median; Q1&#x02013;Q3) of the two study groups (PPS)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">CaMg</th><th align="left" rowspan="1" colspan="1">Sevelamer-HCl</th><th align="left" rowspan="1" colspan="1">Significance Mann&#x02013;
Whitney test (P)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Phosphorus (mmol/L), <italic>n</italic> = 105/99</td><td rowspan="1" colspan="1">2.41; 2.05&#x02013;2.73</td><td rowspan="1" colspan="1">2.42; 2.12&#x02013;2.78</td><td rowspan="1" colspan="1">0.6762</td></tr><tr><td rowspan="1" colspan="1">Total calcium (mmol/L), <italic>n</italic> = 105/99</td><td rowspan="1" colspan="1">2.20; 2.03&#x02013;2.30</td><td rowspan="1" colspan="1">2.17; 2.09&#x02013;2.31</td><td rowspan="1" colspan="1">0.6418</td></tr><tr><td rowspan="1" colspan="1">Ionized calcium (mmol/L), <italic>n</italic> = 99/91</td><td rowspan="1" colspan="1">1.09; 1.01&#x02013;1.16</td><td rowspan="1" colspan="1">1.09; 1.03&#x02013;1.16</td><td rowspan="1" colspan="1">0.6147</td></tr><tr><td rowspan="1" colspan="1">Magnesium (mmol/L), <italic>n</italic> = 105/99</td><td rowspan="1" colspan="1">0.98; 0.89&#x02013;1.09</td><td rowspan="1" colspan="1">0.99; 0.89&#x02013;1.09</td><td rowspan="1" colspan="1">0.9046</td></tr><tr><td rowspan="1" colspan="1">Actual bicarbonate (mmol/L), <italic>n</italic> = 93/84</td><td rowspan="1" colspan="1">21.3; 19.1&#x02013;23.2</td><td rowspan="1" colspan="1">20.9; 18.8&#x02013;22.9</td><td rowspan="1" colspan="1">0.6884</td></tr><tr><td rowspan="1" colspan="1">iPTH (pg/mL), <italic>n</italic> = 102/96</td><td rowspan="1" colspan="1">390; 251&#x02013;607</td><td rowspan="1" colspan="1">422; 286&#x02013;557</td><td rowspan="1" colspan="1">0.9486</td></tr><tr><td rowspan="1" colspan="1">iFGF-23 (pg/mL), <italic>n</italic> = 100/96</td><td rowspan="1" colspan="1">570; 251&#x02013;1741</td><td rowspan="1" colspan="1">779; 278&#x02013;1769</td><td rowspan="1" colspan="1">0.3334</td></tr><tr><td rowspan="1" colspan="1">Log iFGF-23 (pg/mL), <italic>n</italic> = 100/96</td><td rowspan="1" colspan="1">6.3; 5.5&#x02013;7.5</td><td rowspan="1" colspan="1">6.7; 5.6&#x02013;7.5</td><td rowspan="1" colspan="1">0.3334</td></tr><tr><td rowspan="1" colspan="1">AP (U/L), <italic>n</italic> = 105/99</td><td rowspan="1" colspan="1">90; 69&#x02013;110</td><td rowspan="1" colspan="1">88; 66&#x02013;115</td><td rowspan="1" colspan="1">0.6598</td></tr><tr><td rowspan="1" colspan="1">Bone AP (U/L), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">25.4; 16.5&#x02013;33.5</td><td rowspan="1" colspan="1">23.1; 17.9&#x02013;32.3</td><td rowspan="1" colspan="1">0.4866</td></tr><tr><td rowspan="1" colspan="1">Total P1NP (&#x000b5;g/L), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">403.9; 289.5&#x02013;606.5</td><td rowspan="1" colspan="1">425.5; 271.5&#x02013;670.6</td><td rowspan="1" colspan="1">0.9470</td></tr><tr><td rowspan="1" colspan="1">OPG (pmol/L), <italic>n</italic> = 96/95</td><td rowspan="1" colspan="1">19.47; 12.99&#x02013;24.24</td><td rowspan="1" colspan="1">15.78; 12.43&#x02013;21.68</td><td rowspan="1" colspan="1">0.0568</td></tr><tr><td rowspan="1" colspan="1">&#x003b2;-CTx (pg/mL), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">2552; 1806&#x02013;3357</td><td rowspan="1" colspan="1">2818; 1726&#x02013;3544</td><td rowspan="1" colspan="1">0.3491</td></tr><tr><td rowspan="1" colspan="1">TRAP 5b (U/L), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">3.3; 2.1&#x02013;5.3</td><td rowspan="1" colspan="1">3.3; 2.2&#x02013;5.5</td><td rowspan="1" colspan="1">0.8050</td></tr><tr><td rowspan="1" colspan="1">25-(OH) vitamin D<sub>3</sub> (ng/mL), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">38; 20&#x02013;50</td><td rowspan="1" colspan="1">33; 24&#x02013;60</td><td rowspan="1" colspan="1">0.6571</td></tr><tr><td rowspan="1" colspan="1">1,25-(OH)<sub>2</sub> vitamin D<sub>3</sub> (pmol/L), <italic>n</italic> = 99/95</td><td rowspan="1" colspan="1">16.2; 10.2&#x02013;22.9</td><td rowspan="1" colspan="1">14.1; 10.7&#x02013;20.3</td><td rowspan="1" colspan="1">0.3964</td></tr></tbody></table><table-wrap-foot><fn><p>AP, alkaline phosphatase; &#x003b2;-CTx, beta-crosslaps; CaMg; calcium acetate/magnesium carbonate; HCI, hydrochloride; iFGF-23, intact fibroblast growth factor-23; iPTH, intact parathyroid hormone; OPG, osteoprotegerin; P1NP, procollagen type 1 amino-terminal propeptide; PPS, per protocol set; TRAP 5b, tartrate-resistant acid phosphatase 5b.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="gft203_s3b"><title>Mineral metabolism and intact parathyroid hormone</title><p>Parameters of mineral metabolism and iPTH at Weeks 1, 9 and 25 are given in Table&#x000a0;<xref ref-type="table" rid="GFT203TB2">2</xref>. Data analysed from the PPS confirmed the results of the primary analysis involving the full analysis set regarding mineral metabolism in both of the groups [<xref ref-type="bibr" rid="GFT203C7">7</xref>]. Major changes in P, actual bicarbonate and total Ca (only in the CaMg group) and iPTH occurred during the first 9 weeks&#x02014;the phosphate-lowering phase of the study. Changes in serum P from Weeks 1&#x02013;25 for both of the groups are shown in Figure&#x000a0;<xref ref-type="fig" rid="GFT203F1">1</xref>a. Changes in iPTH from Weeks 1&#x02013;9 correlated significantly with changes in serum P, for both treatment arms (<italic>r</italic> = 0.44, P &#x0003c; 0.0001 for CaMg and <italic>r</italic> = 0.37, P = 0.0002 for sevelamer-HCl, respectively). In addition, in the CaMg group they were also inversely related to changes in total (<italic>r</italic> = &#x02212;0.35, P = 0.0003) and ionized serum Ca (<italic>r</italic> = &#x02212;0.27, P = 0.0065), Mg (<italic>r</italic> = &#x02212;0.34, P = 0.0005) and actual bicarbonate (<italic>r</italic> = &#x02212;0.21, P = 0.0458) (<ext-link ext-link-type="uri" xlink:href="http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft203/-/DC1">Supplementary data, Table S1</ext-link>).<table-wrap id="GFT203TB2" position="float"><label>Table&#x000a0;2.</label><caption><p>Median (Q1&#x02013;Q3) serum minerals, actual bicarbonate and intact parathyroid hormone parameters of the two study groups (PPS) at baseline, Weeks 9 and 25 (for the statistical analyses between treatment groups, values were adjusted for the baseline value, centre and covariates)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Laboratory parameter</th><th align="left" colspan="5" rowspan="1">CaMg<hr/></th><th align="left" colspan="5" rowspan="1">Sevelamer-HCl<hr/></th><th align="left" rowspan="2" colspan="1">Significance (between groups) ANCOVA (repeated measures)</th></tr><tr><th align="left" rowspan="1" colspan="1">Week 1</th><th align="left" rowspan="1" colspan="1">Week 9</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W1 versus W9)</th><th align="left" rowspan="1" colspan="1">Week 25</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W9 versus W25)</th><th align="left" rowspan="1" colspan="1">Week 1</th><th align="left" rowspan="1" colspan="1">Week 9</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W1 versus W9)</th><th align="left" rowspan="1" colspan="1">Week 25</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W9 versus W25)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Phosphorus (mmol/L)</td><td rowspan="1" colspan="1">2.41; 2.05&#x02013;2.73</td><td rowspan="1" colspan="1">1.65; 1.35&#x02013;2.04</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.66; 1.30&#x02013;1.98</td><td rowspan="1" colspan="1">P = 0.4802</td><td rowspan="1" colspan="1">2.42; 2.12&#x02013;2.78</td><td rowspan="1" colspan="1">1.78; 1.45&#x02013;2.10</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.69; 1.32&#x02013;2.02</td><td rowspan="1" colspan="1">P = 0.7013</td><td rowspan="1" colspan="1">P = 0.1635</td></tr><tr><td rowspan="1" colspan="1">Total calcium (mmol/L)</td><td rowspan="1" colspan="1">2.20; 2.03&#x02013;2.30</td><td rowspan="1" colspan="1">2.22; 2.13&#x02013;2.36</td><td rowspan="1" colspan="1">P = 0.0001</td><td rowspan="1" colspan="1">2.24; 2.14&#x02013;2.34</td><td rowspan="1" colspan="1">P = 0.8032</td><td rowspan="1" colspan="1">2.17; 2.09&#x02013;2.31</td><td rowspan="1" colspan="1">2.22; 2.11&#x02013;2.31</td><td rowspan="1" colspan="1">P = 0.3285</td><td rowspan="1" colspan="1">2.20; 2.06&#x02013;2.30</td><td rowspan="1" colspan="1">P = 0.0565</td><td rowspan="1" colspan="1">P = 0.0053</td></tr><tr><td rowspan="1" colspan="1">Ionized calcium (mmol/L)</td><td rowspan="1" colspan="1">1.09; 1.01&#x02013;1.16</td><td rowspan="1" colspan="1">1.13; 1.08&#x02013;1.18</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.13; 1.07&#x02013;1.19</td><td rowspan="1" colspan="1">P = 0.9442</td><td rowspan="1" colspan="1">1.09; 1.03&#x02013;1.16</td><td rowspan="1" colspan="1">1.13; 1.09&#x02013;1.19</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.13; 1.07&#x02013;1.18</td><td rowspan="1" colspan="1">P = 0.0588</td><td rowspan="1" colspan="1">P = 0.7356</td></tr><tr><td rowspan="1" colspan="1">Magnesium (mmol/L)</td><td rowspan="1" colspan="1">0.98; 0.89&#x02013;1.09</td><td rowspan="1" colspan="1">1.26; 1.15&#x02013;1.41</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.28; 1.15&#x02013;1.46</td><td rowspan="1" colspan="1">P = 0.2868</td><td rowspan="1" colspan="1">0.99; 0.89&#x02013;1.09</td><td rowspan="1" colspan="1">1.07; 0.96&#x02013;1.17</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">1.04; 0.95&#x02013;1.15</td><td rowspan="1" colspan="1">P = 0.0537</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">Actual bicarbonate (mmol/L)</td><td rowspan="1" colspan="1">21.3; 19.1&#x02013;23.2</td><td rowspan="1" colspan="1">23.3; 21.2&#x02013;25.3</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">23.0; 20.3&#x02013;25.2</td><td rowspan="1" colspan="1">P = 0.8501</td><td rowspan="1" colspan="1">20.9; 18.8&#x02013;22.9</td><td rowspan="1" colspan="1">20.2; 18.1&#x02013;22.9</td><td rowspan="1" colspan="1">P = 0.0442</td><td rowspan="1" colspan="1">20.2; 17.8&#x02013;23.6</td><td rowspan="1" colspan="1">P = 0.4566</td><td rowspan="1" colspan="1">P = 0.0002</td></tr><tr><td rowspan="1" colspan="1">iPTH (pg/mL)</td><td rowspan="1" colspan="1">390; 251&#x02013;607</td><td rowspan="1" colspan="1">283; 187&#x02013;478</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">312; 159&#x02013;436</td><td rowspan="1" colspan="1">P = 0.1159</td><td rowspan="1" colspan="1">422; 286&#x02013;557</td><td rowspan="1" colspan="1">345; 217&#x02013;468</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">373; 227&#x02013;521</td><td rowspan="1" colspan="1">P = 0.0896</td><td rowspan="1" colspan="1">P = 0.0553</td></tr></tbody></table><table-wrap-foot><fn><p>ANCOVA, analysis of covariance; CaMg; calcium acetate/magnesium carbonate; HCI, hydrochloride; iPTH, intact parathyroid hormone; PPS, per protocol set.</p></fn></table-wrap-foot></table-wrap><fig id="GFT203F1" position="float"><label>FIGURE&#x000a0;1:</label><caption><p>View of selected parameters from <xref ref-type="table" rid="GFT203TB2">Tables&#x000a0;2</xref> and <xref ref-type="table" rid="GFT203TB3">3</xref> to illustrate the impact of phosphate binders on serum levels of (<bold>a</bold>) phosphorus, (<bold>b</bold>) log-intact FGF-23, (<bold>c</bold>) bone AP and (<bold>d</bold>) beta-crosslaps. Time course of values at Weeks 9 and 25 of the calcium acetate/magnesium carbonate group (<italic>n</italic> = 105) and of the sevelamer-HCl group (<italic>n</italic> = 99) (PPS) is displayed in white and grey, respectively. Probability values are the result of the Wilcoxon test for within-group significance (Week 9 versus Week 1 and Week 25 versus Week 9, respectively) and repeated measures ANCOVA for between-group evaluation (indicated by asterisks). The plotted values indicate medians and interquartile range, with 10th and 90th percentiles as the error bars.</p></caption><graphic xlink:href="gft20301"/></fig></p></sec><sec id="gft203_s3c"><title>Intact fibroblast growth factor-23</title><p>Intact FGF-23 (iFGF-23) and log iFGF-23 declined significantly during treatment with both phosphate binders, specifically during the first 9 weeks of treatment, with no difference between groups after 25 weeks of treatment (ANCOVA, P = 0.1573) (Table&#x000a0;<xref ref-type="table" rid="GFT203TB3">3</xref> and Figure&#x000a0;<xref ref-type="fig" rid="GFT203F1">1</xref>b). iFGF-23 strongly correlated with serum P (Week 25 all patients: <italic>r</italic> = 0.34, P &#x0003c; 0.0001) at all time points in both of the groups. However, the change in iFGF-23 correlated with the change in serum P in the CaMg group (<italic>r</italic> = 0.36, P = 0.0002), but not in the sevelamer-HCl group (<italic>r</italic> = 0.11, P = 0.3047). In addition, the change in iFGF-23 correlated inversely with the change in serum Mg (<italic>r</italic> = &#x02212;0.28, P = 0.0047) in the CaMg group. No correlations of the change in iFGF-23 with changes in ionized or total Ca were observed in either group. The change in iFGF-23 was found to correlate weakly with a change in iPTH, but only in the sevelamer-HCl group and only in the first part of the study (<ext-link ext-link-type="uri" xlink:href="http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft203/-/DC1">Supplementary data, Table S1</ext-link>).<table-wrap id="GFT203TB3" position="float"><label>Table&#x000a0;3.</label><caption><p>Median (Q1&#x02013;Q3) serum bone regulating factors and markers of the two study groups (PPS) at baseline, Weeks 9 and 25 (for the statistical analyses between treatment groups, values were adjusted for the baseline value, centre and covariates)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Laboratory parameter</th><th align="left" colspan="5" rowspan="1">CaMg<hr/></th><th align="left" colspan="5" rowspan="1">Sevelamer-HCl<hr/></th><th align="left" rowspan="2" colspan="1">Significance (between groups) ANCOVA (repeated measures)</th></tr><tr><th align="left" rowspan="1" colspan="1">Week 1</th><th align="left" rowspan="1" colspan="1">Week 9</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W1 versus W9)</th><th align="left" rowspan="1" colspan="1">Week 25</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W9 versus W25)</th><th align="left" rowspan="1" colspan="1">Week 1</th><th align="left" rowspan="1" colspan="1">Week 9</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W1 versus W9)</th><th align="left" rowspan="1" colspan="1">Week 25</th><th align="left" rowspan="1" colspan="1">Wilcoxon test (W9 versus W25)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">iFGF-23 (pg/mL)</td><td rowspan="1" colspan="1">570; 251&#x02013;1741</td><td rowspan="1" colspan="1">327; 138&#x02013;1104</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">343; 145&#x02013;894</td><td rowspan="1" colspan="1">P = 0.4881</td><td rowspan="1" colspan="1">779; 278&#x02013;1769</td><td rowspan="1" colspan="1">404; 137&#x02013;962</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">309; 121&#x02013;736</td><td rowspan="1" colspan="1">P = 0.0047</td><td rowspan="1" colspan="1">P = 0.0705</td></tr><tr><td rowspan="1" colspan="1">Log iFGF-23 (pg/mL)</td><td rowspan="1" colspan="1">6.3; 5.5&#x02013;7.5</td><td rowspan="1" colspan="1">5.8; 4.9&#x02013;7.0</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">5.8; 5.0&#x02013;6.8</td><td rowspan="1" colspan="1">P = 0.5516</td><td rowspan="1" colspan="1">6.7; 5.6&#x02013;7.5</td><td rowspan="1" colspan="1">6.0; 4.9&#x02013;6.9</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">5.7; 4.8&#x02013;6.6</td><td rowspan="1" colspan="1">P = 0.0011</td><td rowspan="1" colspan="1">P = 0.1573</td></tr><tr><td rowspan="1" colspan="1">AP (U/L)</td><td rowspan="1" colspan="1">90; 69&#x02013;110</td><td rowspan="1" colspan="1">94; 74&#x02013;132</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">87; 71&#x02013;130</td><td rowspan="1" colspan="1">P = 0.3955</td><td rowspan="1" colspan="1">88; 66&#x02013;115</td><td rowspan="1" colspan="1">109; 83&#x02013;146</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">117; 94&#x02013;145</td><td rowspan="1" colspan="1">P = 0.0315</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">Bone AP (U/L)</td><td rowspan="1" colspan="1">25.4; 16.5&#x02013;33.5</td><td rowspan="1" colspan="1">28.5; 18.2&#x02013;42.1</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">29.2; 18.5&#x02013;40.5</td><td rowspan="1" colspan="1">P = 0.0909</td><td rowspan="1" colspan="1">23.1; 17.9&#x02013;32.3</td><td rowspan="1" colspan="1">30.5; 22.7&#x02013;43.6</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">36.4; 27.1&#x02013;47.1</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">Total P1NP (&#x000b5;g/L)</td><td rowspan="1" colspan="1">403.9; 289.5&#x02013;606.5</td><td rowspan="1" colspan="1">377.4; 264.1&#x02013;640.4</td><td rowspan="1" colspan="1">P = 0.1041</td><td rowspan="1" colspan="1">385.4; 249.0&#x02013;613.2</td><td rowspan="1" colspan="1">P = 0.7522</td><td rowspan="1" colspan="1">425.5; 271.5&#x02013;670.6</td><td rowspan="1" colspan="1">460.1; 337.2&#x02013;742.4</td><td rowspan="1" colspan="1">P = 0.0014</td><td rowspan="1" colspan="1">518.3; 331.9&#x02013;803.5</td><td rowspan="1" colspan="1">P = 0.0006</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">Osteoprotegerin (pmol/L)</td><td rowspan="1" colspan="1">19.47; 12.99&#x02013;24.24</td><td rowspan="1" colspan="1">20.13; 13.90&#x02013;24.58</td><td rowspan="1" colspan="1">P = 0.1674</td><td rowspan="1" colspan="1">18.74; 13.43&#x02013;25.18</td><td rowspan="1" colspan="1">P = 0.9779</td><td rowspan="1" colspan="1">15.78; 12.43&#x02013;21.68</td><td rowspan="1" colspan="1">16.75; 12.68&#x02013;23.14</td><td rowspan="1" colspan="1">P = 0.0888</td><td rowspan="1" colspan="1">16.80; 14.16&#x02013;23.32</td><td rowspan="1" colspan="1">P = 0.3097</td><td rowspan="1" colspan="1">P = 0.1718</td></tr><tr><td rowspan="1" colspan="1">&#x003b2;-CTx (pg/mL)</td><td rowspan="1" colspan="1">2552; 1806&#x02013;3357</td><td rowspan="1" colspan="1">2200; 1373&#x02013;2921</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">2264; 1354&#x02013;2821</td><td rowspan="1" colspan="1">P = 0.2378</td><td rowspan="1" colspan="1">2818; 1726&#x02013;3544</td><td rowspan="1" colspan="1">2855; 2158&#x02013;3685</td><td rowspan="1" colspan="1">P = 0.4130</td><td rowspan="1" colspan="1">3308; 2288&#x02013;4200</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">TRAP 5b (U/L)</td><td rowspan="1" colspan="1">3.3; 2.1&#x02013;5.3</td><td rowspan="1" colspan="1">3.3; 2.1&#x02013;4.9</td><td rowspan="1" colspan="1">P = 0.1201</td><td rowspan="1" colspan="1">3.6; 2.3&#x02013;5.5</td><td rowspan="1" colspan="1">P = 0.0013</td><td rowspan="1" colspan="1">3.3; 2.2&#x02013;5.5</td><td rowspan="1" colspan="1">3.9; 2.8&#x02013;5.8</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td><td rowspan="1" colspan="1">4.7; 3.2&#x02013;6.5</td><td rowspan="1" colspan="1">P = 0.0008</td><td rowspan="1" colspan="1">P &#x0003c; 0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>ANCOVA, analysis of covariance; AP, alkaline phosphatase; &#x003b2;-CTx, beta-crosslaps; CaMg; calcium acetate/magnesium carbonate; HCI, hydrochloride; iFGF-23, intact fibroblast growth factor 23; P1NP, procollagen type 1 amino-terminal propeptide; PPS, per protocol set; TRAP 5b, tartrate-resistant acid phosphatase 5b.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="gft203_s3d"><title>Bone parameters</title><p>Over the entire treatment period, all bone markers increased significantly in the sevelamer-HCl group (P &#x0003c; 0.0001 for all, except OPG, P = 0.0100 and &#x003b2;-CTx, P = 0.0003). In the CaMg group, bone markers showed a more differentiated behaviour. BAP and AP also increased (P &#x0003c; 0.0001 and P = 0.0018, respectively), but to a lower degree than in the sevelamer group (ANCOVA, both P &#x0003c; 0.0001). P1NP (P = 0.1228), OPG (P = 0.0906) and TRAP 5b (P = 0.3930) remained unchanged. &#x003b2;-CTx decreased significantly over time (P = 0.0004), although the decrease occurred only during the first period (Weeks 1&#x02013;9) (Table&#x000a0;<xref ref-type="table" rid="GFT203TB3">3</xref>).</p><p>When analysing the data separately for the two investigation periods (Weeks 1&#x02013;9 and 9&#x02013;25), more pronounced changes were observed from Weeks 1&#x02013;9 in both of the groups. In the CaMg group, TRAP 5b was the only marker that increased significantly from Weeks 9 to 25. However, in the sevelamer-HCl group, significant increases were seen for BAP, P1NP, &#x003b2;-CTx and TRAP 5b from Weeks 9&#x02013;25 (Table&#x000a0;<xref ref-type="table" rid="GFT203TB3">3</xref>, Figure&#x000a0;<xref ref-type="fig" rid="GFT203F1">1</xref>c and d).</p><p>Changes in AP and BAP did not correlate with changes in iPTH or iFGF-23 in either group. However, from Weeks 1 to 25 changes in other bone markers correlated with changes in iPTH: for sevelamer-HCl, with P1NP, &#x003b2;-CTx, TRAP 5b and inversely with OPG; for the CaMg group, only with P1NP and TRAP 5b (<ext-link ext-link-type="uri" xlink:href="http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft203/-/DC1">Supplementary data, Table S1</ext-link>).</p></sec></sec><sec sec-type="discussion" id="gft203_s4"><title>DISCUSSION</title><p>The aim of this <italic>post hoc</italic> analysis of the randomized, controlled CALMAG study was to determine the impact of phosphate binder therapy on serum levels of FGF-23 and bone markers and to explore whether a difference exists between combined Ca and Mg salts and a non-Ca-containing phosphate binder.</p><sec id="gft203_s4a"><title>Decrease in serum levels of fibroblast growth factor-23</title><p>The study confirmed that serum levels of FGF-23 decreased significantly with both CaMg and sevelamer-HCl during the study period, with no difference between groups at Week 25. Furthermore, FGF-23 levels strongly correlated with serum P levels at all time points in both of the groups; however, changes over the whole study period in serum P correlated with changes in iFGF-23 only in the CaMg group. Similarly, in this group changes in serum Mg over time inversely correlated with changes in iFGF-23.</p><p>While a greater reduction in iFGF-23 with sevelamer-HCl versus Ca acetate has been reported in other studies [<xref ref-type="bibr" rid="GFT203C21">21</xref>, <xref ref-type="bibr" rid="GFT203C22">22</xref>], our investigation clearly shows that the phosphate binder CaMg leads to similar effects. Differences between Weeks 1 and 9, and Weeks 9 and 25, point to the important role of P on levels of hormones such as FGF-23 and iPTH and on bone turnover. However, it is not clear whether the reason underlying the greater reduction in FGF-23 in both of the groups in the first phase is attributable to the effect of the phosphate binder on serum P alone or whether the binder itself has an intrinsic effect, especially since no correlation could be established between any parameter in this phase (with the exception of a weak correlation between iFGF-23 and iPTH in the sevelamer-HCl group).</p><p>Vitamin D strongly influences iFGF-23 levels [<xref ref-type="bibr" rid="GFT203C25">25</xref>] and administration of vitamin D in patients on dialysis leads to an increase of iFGF-23 levels [<xref ref-type="bibr" rid="GFT203C26">26</xref>]. In our study, the dose of vitamin D (independent of whether it was prescribed as a supplementation or as active vitamin D) remained constant and there was no difference between treatment arms; thus, we could not observe any relationship to iFGF-23 levels (data not shown).</p></sec><sec id="gft203_s4b"><title>Additional factors that may influence the levels of fibroblast growth factor-23</title><p>As previously described [<xref ref-type="bibr" rid="GFT203C21">21</xref>], other factors that determine serum Ca and/or Ca balance (oral intake, vitamin D administration, dialysate Ca concentration) may also have an impact on the extent of FGF-23 decrease. In our study, the slight increase in serum iCa in both groups and the very small increase in total serum Ca for CaMg did not play a role in attenuating the decrease in FGF-23 (<ext-link ext-link-type="uri" xlink:href="http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft203/-/DC1">Supplementary data, Table S1</ext-link>) [<xref ref-type="bibr" rid="GFT203C27">27</xref>]. Similar results were reported in an acute study in HD patients with elevated PTH levels investigating the effect of high and low serum Ca with the use of different dialysate Ca concentrations. In the same study, no direct relationship between Ca levels and iFGF-23 could be established [<xref ref-type="bibr" rid="GFT203C28">28</xref>]. In contrast, an association between serum Ca changes and log iFGF-23 was reported in a separate long-term study [<xref ref-type="bibr" rid="GFT203C29">29</xref>].</p><p>Our data suggest that an increase in Mg might be another factor that can influence the decrease in iFGF-23. A possible and hitherto unknown direct or indirect physiological interaction remains to be elucidated. FGF-23 lowering might also be modulated via the Ca-sensing receptor [<xref ref-type="bibr" rid="GFT203C29">29</xref>], and perhaps the reason that no correlation was found between the decline of iPTH and iFGF-23 in the CaMg group may be attributable to the effects of Mg on the Ca-sensing receptor. A similar finding was described in the secondary analysis of a study investigating the effect of cinacalcet on FGF-23 [<xref ref-type="bibr" rid="GFT203C29">29</xref>]. A direct relationship between iPTH and iFGF-23 was not found; however, the authors discussed a direct effect or an indirect mechanism via the Ca-sensing receptor and/or phosphate lowering as a possible explanation [<xref ref-type="bibr" rid="GFT203C29">29</xref>]. In our study, a direct, albeit weak, correlation is evident between iFGF-23 and the decrease in iPTH from Weeks 1 to 9 in the sevelamer-HCl group, which is not surprising in patients with CKD, in whom a direct effect of PTH on FGF-23 mRNA has previously been described [<xref ref-type="bibr" rid="GFT203C20">20</xref>].</p></sec><sec id="gft203_s4c"><title>Differing effects of phosphate binders on bone parameters</title><p>In general, there was a more significant increase in markers of bone turnover in the sevelamer-HCl group compared with the CaMg group, especially after the initial phase of P lowering. This suggests that while control of P levels with CaMg is associated with a similar reduction in serum levels of FGF-23 as with sevelamer-HCl, the influence of CaMg on bone turnover markers is less pronounced.</p><p>Interestingly, while iPTH levels dropped significantly during the first 9 weeks in both of the groups, bone parameters such as BAP increased. While the changes in the levels of BAP and iPTH frequently tend to correlate positively with each other [<xref ref-type="bibr" rid="GFT203C30">30</xref>, <xref ref-type="bibr" rid="GFT203C31">31</xref>], a lack of correlation between these two parameters has also been documented [<xref ref-type="bibr" rid="GFT203C32">32</xref>]. In our longitudinal study, the initial lowering of iPTH is most probably caused by the direct effect of P on the parathyroid gland [<xref ref-type="bibr" rid="GFT203C33">33</xref>, <xref ref-type="bibr" rid="GFT203C34">34</xref>], while the increase in membrane-bound enzyme BAP probably reflects the normalization in osteoblast activity following the same reduction in serum P levels (that is, the effects on bone-remodelling and BAP levels are independent of the effect on the parathyroid gland).</p><p>In line with other studies [<xref ref-type="bibr" rid="GFT203C23">23</xref>, <xref ref-type="bibr" rid="GFT203C35">35</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C38">38</xref>], a more pronounced increase in bone markers with sevelamer-HCl in comparison to CaMg was evident in our study. This may represent some clinical benefit, for example, in patients with low bone turnover disease [<xref ref-type="bibr" rid="GFT203C36">36</xref>], or it may reflect an aggravation of secondary hyperparathyroidism [<xref ref-type="bibr" rid="GFT203C31">31</xref>]. Furthermore, an increased level of AP is associated with increased mortality, as recently reported in epidemiological studies [<xref ref-type="bibr" rid="GFT203C39">39</xref>, <xref ref-type="bibr" rid="GFT203C40">40</xref>]. However, whether an increase in markers associated with bone mineral loss [<xref ref-type="bibr" rid="GFT203C41">41</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C43">43</xref>], such as TRAP 5b and OPG seen in the patients on sevelamer-HCl, can lead to an apparent clinical effect is an issue that requires further investigation.</p><p>Although the ideal levels of bone markers in patients receiving dialysis remain to be established, the use of CaMg as a phosphate binder appears to moderately correct levels towards the normal range and prevents a continuous increase. The lack of a placebo group in this study limits the extent to which we can detail relative effects of phosphate binders on bone turnover. Nevertheless, a recent investigation of several different phosphate binders, which also included a placebo group, in pre-dialysis patients similarly showed differential changes in bone mineral density, depending on the phosphate binder or placebo use, further supporting our findings [<xref ref-type="bibr" rid="GFT203C44">44</xref>]. However, the reason for the different effects of both phosphate binders on bone parameters in the current study remains to be elucidated. Possibilities include an effect of Ca and Mg, as well as an effect of acid&#x02013;base status on the bone turnover [<xref ref-type="bibr" rid="GFT203C45">45</xref>, <xref ref-type="bibr" rid="GFT203C46">46</xref>], which improved with CaMg but remained unchanged in the sevelamer-HCl group [<xref ref-type="bibr" rid="GFT203C7">7</xref>].</p><p>There is a concern that increased serum Mg levels may potentially have a harmful effect on bone, such as mineralization defects and adynamic bone disease, in dialysis patients [<xref ref-type="bibr" rid="GFT203C47">47</xref>]. In contrast, Mg levels in the upper normal range in the general population and mildly elevated levels in patients with CKD 5 have in fact been associated with benefits, including reduced cardiovascular calcification, reduced hypertension and reduced mortality [<xref ref-type="bibr" rid="GFT203C47">47</xref>&#x02013;<xref ref-type="bibr" rid="GFT203C49">49</xref>].</p><p>In our study, we did not perform bone biopsies, which is a major limitation, and therefore we cannot exclude the possibility of development of adynamic bone disease. However, the observed lack of decrease in bone formation markers such as BAP, known for its high specificity and sensitivity in identifying bone remodelling when compared with bone biopsies [<xref ref-type="bibr" rid="GFT203C30">30</xref>, <xref ref-type="bibr" rid="GFT203C31">31</xref>], supports the absence of adynamic bone disease. In addition, a large bone biopsy study in 100 patients did not find Mg bone content to be correlated with osteomalacia or any other type of bone disease, even though the Mg/Ca ratio was elevated in dialysis patients compared with healthy controls [<xref ref-type="bibr" rid="GFT203C50">50</xref>]. Furthermore, in 35 patients in the same study who were diagnosed with adynamic bone disease, the Mg content of bone biopsies did not differ significantly from other types of renal osteodystrophy.</p><p>In summary, in contrast to the sevelamer group, bone marker changes over time indicate that CaMg helps maintain bone health, causing neither an overstimulation nor a suppression of bone turnover.</p></sec></sec><sec sec-type="conclusions" id="gft203_s5"><title>CONCLUSION</title><p>This study provides an intriguing insight into the therapeutic effects of the phosphate binders CaMg and sevelamer-HCl on FGF-23 and bone markers. The differing effects of phosphate binders on bone metabolism reinforce the need for studying these effects for each respective phosphate binder separately [<xref ref-type="bibr" rid="GFT203C44">44</xref>]. Limitations of the study are that it did not include a placebo control and we did not conduct any bone biopsies. Further studies are required to understand better the reason(s) underlying the different effects of CaMg and sevelamer-HCl on FGF-23 and bone parameters.</p><p>In conclusion, CaMg lowered serum levels of iFGF-23 to the same extent as sevelamer-HCl in this controlled, randomized study. Changes in bone parameters were dependent on the characteristics of each phosphate binder. CaMg resulted in an increase in serum Mg but did not have a distinct effect on bone turnover markers.</p></sec><sec id="gft203_s6"><title>SUPPLEMENTARY DATA</title><p><ext-link ext-link-type="uri" xlink:href="http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gft203/-/DC1">Supplementary data are available online at</ext-link>
<uri xlink:type="simple" xlink:href="http://ndt.oxfordjournals.org">http://ndt.oxfordjournals.org</uri>.</p></sec><sec id="gft203_s7"><title>CONFLICT OF INTEREST STATEMENT</title><p>This study was presented as an abstract at the meeting of the European Renal Association-European Dialysis and Transplant Association; Prague, Czech Republic; 23&#x02013;26 June 2011; otherwise, the results presented in this paper have not been published previously in whole or part.</p><p>A.C. is an adviser to FMC, Affymax and has received speakers' honoraria from Abbott, Amgen and Vifor. J.P.-D is a consultant to Fresenius Medical Care. M.K. serves as the responsible nephrologist at a Fresenius NephroCare dialysis centre. B.B.-S. states no conflict of interest. A.G. serves as the responsible nephrologist at a Fresenius NephroCare dialysis centre. P.P. serves as the Portuguese Country Medical Director at a Fresenius NephroCare dialysis centre. B.M. is an employee of Fresenius Medical Care Deutschland GmbH, Bad Homburg. A.L.M. de F. is an adviser to Amgen and has received speakers' honoraria from Abbott, Amgen, Fresenius and Gambro.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_28_9_2383__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_gft203_gft203supp.docx"/>
</supplementary-material>
</sec>
</body><back><ack><title>ACKNOWLEDGEMENTS</title><p>Medical writing assistance was provided by Shilpa Aggarwal, ApotheCom ScopeMedical Ltd, funded by Fresenius Medical Care. This study was funded by <funding-source>Fresenius Medical Care</funding-source>.</p></ack><ref-list><title>REFERENCES</title><ref id="GFT203C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Hulbert-Shearon</surname><given-names>TE</given-names></name><name><surname>Levin</surname><given-names>NW</given-names></name><etal/></person-group><article-title>Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>31</volume><fpage>607</fpage><lpage>617</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/ajkd.1998.v31.pm9531176">doi:10.1053/ajkd.1998.v31.pm9531176</ext-link></comment><pub-id pub-id-type="pmid">9531176</pub-id></element-citation></ref><ref id="GFT203C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covic</surname><given-names>A</given-names></name><name><surname>Kothawala</surname><given-names>P</given-names></name><name><surname>Bernal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>1506</fpage><lpage>1523</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfn613">doi:10.1093/ndt/gfn613</ext-link></comment><pub-id pub-id-type="pmid">19001560</pub-id></element-citation></ref><ref id="GFT203C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lezaic</surname><given-names>V</given-names></name><name><surname>Tirmenstajn-Jankovic</surname><given-names>B</given-names></name><name><surname>Bukvic</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification</article-title><source>Clin Nephrol</source><year>2009</year><volume>71</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">19203546</pub-id></element-citation></ref><ref id="GFT203C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plantinga</surname><given-names>LC</given-names></name><name><surname>Fink</surname><given-names>NE</given-names></name><name><surname>Melamed</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Serum phosphate levels and risk of infection in incident dialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><fpage>1398</fpage><lpage>1406</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.00420108">doi:10.2215/CJN.00420108</ext-link></comment><pub-id pub-id-type="pmid">18562596</pub-id></element-citation></ref><ref id="GFT203C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tentori</surname><given-names>F</given-names></name><name><surname>Blayney</surname><given-names>MJ</given-names></name><name><surname>Albert</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>52</volume><fpage>519</fpage><lpage>530</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.ajkd.2008.03.020">doi:10.1053/j.ajkd.2008.03.020</ext-link></comment><pub-id pub-id-type="pmid">18514987</pub-id></element-citation></ref><ref id="GFT203C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>R</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name><name><surname>Tighiouart</surname><given-names>H</given-names></name><etal/></person-group><article-title>Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the hemodialysis (HEMO) study</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>52</volume><fpage>531</fpage><lpage>540</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.ajkd.2008.05.020">doi:10.1053/j.ajkd.2008.05.020</ext-link></comment><pub-id pub-id-type="pmid">18657891</pub-id></element-citation></ref><ref id="GFT203C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Francisco</surname><given-names>AL</given-names></name><name><surname>Leidig</surname><given-names>M</given-names></name><name><surname>Covic</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>3707</fpage><lpage>3717</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfq292">doi:10.1093/ndt/gfq292</ext-link></comment><pub-id pub-id-type="pmid">20530499</pub-id></element-citation></ref><ref id="GFT203C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Meijers</surname><given-names>B</given-names></name><name><surname>Viaene</surname><given-names>L</given-names></name><etal/></person-group><article-title>Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism</article-title><source>Clin J Am Soc Nephrol</source><year>2010</year><volume>5</volume><fpage>1268</fpage><lpage>1276</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.08241109">doi:10.2215/CJN.08241109</ext-link></comment><pub-id pub-id-type="pmid">20448073</pub-id></element-citation></ref><ref id="GFT203C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Klassen</surname><given-names>PS</given-names></name><name><surname>Lazarus</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Mineral metabolism, mortality, and morbidity in maintenance hemodialysis</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>2208</fpage><lpage>2218</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.ASN.0000133041.27682.A2">doi:10.1097/01.ASN.0000133041.27682.A2</ext-link></comment><pub-id pub-id-type="pmid">15284307</pub-id></element-citation></ref><ref id="GFT203C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>M</given-names></name><name><surname>Galassi</surname><given-names>A</given-names></name><name><surname>Apetrii</surname><given-names>M</given-names></name><etal/></person-group><article-title>What would we like to know, and what do we not know about fibroblast growth factor 23?</article-title><source>J Nephrol</source><year>2011</year><volume>24</volume><fpage>696</fpage><lpage>706</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5301/jn.5000003">doi:10.5301/jn.5000003</ext-link></comment><pub-id pub-id-type="pmid">21786227</pub-id></element-citation></ref><ref id="GFT203C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez</surname><given-names>OM</given-names></name><name><surname>Mannstadt</surname><given-names>M</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>584</fpage><lpage>592</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa0706130">doi:10.1056/NEJMoa0706130</ext-link></comment><pub-id pub-id-type="pmid">18687639</pub-id></element-citation></ref><ref id="GFT203C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>2432</fpage><lpage>2439</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2011.826">doi:10.1001/jama.2011.826</ext-link></comment><pub-id pub-id-type="pmid">21673295</pub-id></element-citation></ref><ref id="GFT203C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>G</given-names></name><name><surname>Terrat</surname><given-names>JC</given-names></name><name><surname>Vanel</surname><given-names>T</given-names></name><etal/></person-group><article-title>High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>2792</fpage><lpage>2796</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfp191">doi:10.1093/ndt/gfp191</ext-link></comment><pub-id pub-id-type="pmid">19395730</pub-id></element-citation></ref><ref id="GFT203C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>TE</given-names></name></person-group><article-title>The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>1376</fpage><lpage>1381</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfp784">doi:10.1093/ndt/gfp784</ext-link></comment><pub-id pub-id-type="pmid">20124546</pub-id></element-citation></ref><ref id="GFT203C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komaba</surname><given-names>H</given-names></name><name><surname>Fukagawa</surname><given-names>M</given-names></name></person-group><article-title>FGF23-parathyroid interaction: implications in chronic kidney disease</article-title><source>Kidney Int</source><year>2010</year><volume>77</volume><fpage>292</fpage><lpage>298</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2009.466">doi:10.1038/ki.2009.466</ext-link></comment><pub-id pub-id-type="pmid">20010546</pub-id></element-citation></ref><ref id="GFT203C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krajisnik</surname><given-names>T</given-names></name><name><surname>Bjorklund</surname><given-names>P</given-names></name><name><surname>Marsell</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells</article-title><source>J Endocrinol</source><year>2007</year><volume>195</volume><fpage>125</fpage><lpage>131</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1677/JOE-07-0267">doi:10.1677/JOE-07-0267</ext-link></comment><pub-id pub-id-type="pmid">17911404</pub-id></element-citation></ref><ref id="GFT203C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>K</given-names></name><name><surname>Komaba</surname><given-names>H</given-names></name><name><surname>Fukagawa</surname><given-names>M</given-names></name></person-group><article-title>New insights into the role of fibroblast growth factor 23 in chronic kidney disease</article-title><source>J Nephrol</source><year>2010</year><volume>23</volume><fpage>619</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">20658451</pub-id></element-citation></ref><ref id="GFT203C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>TE</given-names></name></person-group><article-title>FGF23 beyond mineral metabolism: a bridge to cardiovascular disease</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><fpage>2735</fpage><lpage>2737</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.10711011">doi:10.2215/CJN.10711011</ext-link></comment><pub-id pub-id-type="pmid">22157705</pub-id></element-citation></ref><ref id="GFT203C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>S</given-names></name><name><surname>Reichart</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>D</given-names></name><etal/></person-group><article-title>FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>3983</fpage><lpage>3989</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfq309">doi:10.1093/ndt/gfq309</ext-link></comment><pub-id pub-id-type="pmid">20525642</pub-id></element-citation></ref><ref id="GFT203C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Slatopolsky</surname><given-names>E</given-names></name></person-group><article-title>FGF23 and PTH&#x02014;double agents at the heart of CKD</article-title><source>Nephrol Dial Transplant</source><year>2012</year><volume>27</volume><fpage>1715</fpage><lpage>1720</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfs050">doi:10.1093/ndt/gfs050</ext-link></comment><pub-id pub-id-type="pmid">22447519</pub-id></element-citation></ref><ref id="GFT203C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancela</surname><given-names>AL</given-names></name><name><surname>Oliveira</surname><given-names>RB</given-names></name><name><surname>Graciolli</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>117</volume><fpage>c74</fpage><lpage>c82</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000319650">doi:10.1159/000319650</ext-link></comment><pub-id pub-id-type="pmid">20689328</pub-id></element-citation></ref><ref id="GFT203C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>RB</given-names></name><name><surname>Cancela</surname><given-names>AL</given-names></name><name><surname>Graciolli</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD&#x02013;MBD therapy?</article-title><source>Clin J Am Soc Nephrol</source><year>2010</year><volume>5</volume><fpage>286</fpage><lpage>291</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.05420709">doi:10.2215/CJN.05420709</ext-link></comment><pub-id pub-id-type="pmid">19965540</pub-id></element-citation></ref><ref id="GFT203C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Fraz&#x000e3;o</surname><given-names>JM</given-names></name><name><surname>Monier-Faugere</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>405</fpage><lpage>412</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2006101089">doi:10.1681/ASN.2006101089</ext-link></comment><pub-id pub-id-type="pmid">18199805</pub-id></element-citation></ref><ref id="GFT203C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Emerging role of fibroblast growth factor 23 in a bone&#x02013;kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization</article-title><source>Curr Opin Nephrol Hypertens</source><year>2007</year><volume>16</volume><fpage>329</fpage><lpage>335</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MNH.0b013e3281ca6ffd">doi:10.1097/MNH.0b013e3281ca6ffd</ext-link></comment><pub-id pub-id-type="pmid">17565275</pub-id></element-citation></ref><ref id="GFT203C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>1305</fpage><lpage>1315</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2005111185">doi:10.1681/ASN.2005111185</ext-link></comment><pub-id pub-id-type="pmid">16597685</pub-id></element-citation></ref><ref id="GFT203C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishi</surname><given-names>H</given-names></name><name><surname>Nii-Kono</surname><given-names>T</given-names></name><name><surname>Nakanishi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism</article-title><source>Nephron Clin Pract</source><year>2005</year><volume>101</volume><fpage>c94</fpage><lpage>c99</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000086347">doi:10.1159/000086347</ext-link></comment><pub-id pub-id-type="pmid">15956805</pub-id></element-citation></ref><ref id="GFT203C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Ortiz</surname><given-names>ME</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Mu&#x000f1;oz-Castaneda</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Calcium deficiency reduces circulating levels of FGF23</article-title><source>J Am Soc Nephrol</source><year>2012</year><volume>23</volume><fpage>1190</fpage><lpage>1197</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2011101006">doi:10.1681/ASN.2011101006</ext-link></comment><pub-id pub-id-type="pmid">22581996</pub-id></element-citation></ref><ref id="GFT203C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetmore</surname><given-names>JB</given-names></name><name><surname>Santos</surname><given-names>PW</given-names></name><name><surname>Mahnken</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>E57</fpage><lpage>E64</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1210/jc.2010-1277">doi:10.1210/jc.2010-1277</ext-link></comment><pub-id pub-id-type="pmid">20943782</pub-id></element-citation></ref><ref id="GFT203C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>M</given-names></name><name><surname>Komaba</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism</article-title><source>Nephrol Dial Transplant</source><year>2012</year><volume>27</volume><fpage>784</fpage><lpage>790</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfr384">doi:10.1093/ndt/gfr384</ext-link></comment><pub-id pub-id-type="pmid">21730210</pub-id></element-citation></ref><ref id="GFT203C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couttenye</surname><given-names>MM</given-names></name><name><surname>D'Haese</surname><given-names>PC</given-names></name><name><surname>Van Hoof</surname><given-names>VO</given-names></name><etal/></person-group><article-title>Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>1996</year><volume>11</volume><fpage>1065</fpage><lpage>1072</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/oxfordjournals.ndt.a027457">doi:10.1093/oxfordjournals.ndt.a027457</ext-link></comment><pub-id pub-id-type="pmid">8671970</pub-id></element-citation></ref><ref id="GFT203C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ure&#x000f1;a</surname><given-names>P</given-names></name><name><surname>Hruby</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">8704118</pub-id></element-citation></ref><ref id="GFT203C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorge</surname><given-names>C</given-names></name><name><surname>Gil</surname><given-names>C</given-names></name><name><surname>Possante</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients&#x02014;any advantage?</article-title><source>Nephron Clin Pract</source><year>2005</year><volume>101</volume><fpage>c122</fpage><lpage>c127</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000086682">doi:10.1159/000086682</ext-link></comment><pub-id pub-id-type="pmid">16015001</pub-id></element-citation></ref><ref id="GFT203C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almaden</surname><given-names>Y</given-names></name><name><surname>Hernandez</surname><given-names>A</given-names></name><name><surname>Torregrosa</surname><given-names>V</given-names></name><etal/></person-group><article-title>High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro</article-title><source>J Am Soc Nephrol</source><year>1998</year><volume>9</volume><fpage>1845</fpage><lpage>1852</lpage><pub-id pub-id-type="pmid">9773785</pub-id></element-citation></ref><ref id="GFT203C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canalejo</surname><given-names>A</given-names></name><name><surname>Canalejo</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>1087</fpage><lpage>1097</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfp616">doi:10.1093/ndt/gfp616</ext-link></comment><pub-id pub-id-type="pmid">19934096</pub-id></element-citation></ref><ref id="GFT203C35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname><given-names>DV</given-names></name><name><surname>Barreto Fde</surname><given-names>C</given-names></name><name><surname>de Carvalho</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Phosphate binder impact on bone remodeling and coronary calcification&#x02013;results from the BRiC study</article-title><source>Nephron Clin Pract</source><year>2008</year><volume>110</volume><fpage>c273</fpage><lpage>c283</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000170783">doi:10.1159/000170783</ext-link></comment><pub-id pub-id-type="pmid">19001830</pub-id></element-citation></ref><ref id="GFT203C36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels</article-title><source>Intern Med</source><year>2007</year><volume>46</volume><fpage>447</fpage><lpage>452</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2169/internalmedicine.46.6338">doi:10.2169/internalmedicine.46.6338</ext-link></comment><pub-id pub-id-type="pmid">17443033</pub-id></element-citation></ref><ref id="GFT203C37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Lin</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients</article-title><source>Ren Fail</source><year>2006</year><volume>28</volume><fpage>701</fpage><lpage>707</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/08860220600925388">doi:10.1080/08860220600925388</ext-link></comment><pub-id pub-id-type="pmid">17162430</pub-id></element-citation></ref><ref id="GFT203C38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesseling-Perry</surname><given-names>K</given-names></name><name><surname>Harkins</surname><given-names>GC</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols</article-title><source>Pediatr Nephrol</source><year>2009</year><volume>24</volume><fpage>1355</fpage><lpage>1361</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00467-009-1143-8">doi:10.1007/s00467-009-1143-8</ext-link></comment><pub-id pub-id-type="pmid">19301038</pub-id></element-citation></ref><ref id="GFT203C39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blayney</surname><given-names>MJ</given-names></name><name><surname>Pisoni</surname><given-names>RL</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><etal/></person-group><article-title>High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death</article-title><source>Kidney Int</source><year>2008</year><volume>74</volume><fpage>655</fpage><lpage>663</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2008.248">doi:10.1038/ki.2008.248</ext-link></comment><pub-id pub-id-type="pmid">18547993</pub-id></element-citation></ref><ref id="GFT203C40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regidor</surname><given-names>DL</given-names></name><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>2193</fpage><lpage>2203</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2008010014">doi:10.1681/ASN.2008010014</ext-link></comment><pub-id pub-id-type="pmid">18667733</pub-id></element-citation></ref><ref id="GFT203C41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doumouchtsis</surname><given-names>KK</given-names></name><name><surname>Kostakis</surname><given-names>AI</given-names></name><name><surname>Doumouchtsis</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients</article-title><source>J Bone Miner Metab</source><year>2008</year><volume>26</volume><fpage>66</fpage><lpage>72</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00774-007-0785-5">doi:10.1007/s00774-007-0785-5</ext-link></comment><pub-id pub-id-type="pmid">18095066</pub-id></element-citation></ref><ref id="GFT203C42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimori</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>118</volume><fpage>c375</fpage><lpage>c379</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000323669">doi:10.1159/000323669</ext-link></comment><pub-id pub-id-type="pmid">21325869</pub-id></element-citation></ref><ref id="GFT203C43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shidara</surname><given-names>K</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Okuno</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients</article-title><source>Calcif Tissue Int</source><year>2008</year><volume>82</volume><fpage>278</fpage><lpage>287</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00223-008-9127-4">doi:10.1007/s00223-008-9127-4</ext-link></comment><pub-id pub-id-type="pmid">18421493</pub-id></element-citation></ref><ref id="GFT203C44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Wheeler</surname><given-names>DC</given-names></name><name><surname>Persky</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effects of phosphate binders in moderate CKD</article-title><source>J Am Soc Nephrol</source><year>2012</year><volume>23</volume><fpage>1407</fpage><lpage>1415</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2012030223">doi:10.1681/ASN.2012030223</ext-link></comment><pub-id pub-id-type="pmid">22822075</pub-id></element-citation></ref><ref id="GFT203C45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushinsky</surname><given-names>DA</given-names></name><name><surname>Wolbach</surname><given-names>W</given-names></name><name><surname>Sessler</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Physicochemical effects of acidosis on bone calcium flux and surface ion composition</article-title><source>J Bone Miner Res</source><year>1993</year><volume>8</volume><fpage>93</fpage><lpage>102</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jbmr.5650080112">doi:10.1002/jbmr.5650080112</ext-link></comment><pub-id pub-id-type="pmid">8427052</pub-id></element-citation></ref><ref id="GFT203C46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bichara</surname><given-names>M</given-names></name><name><surname>Mercier</surname><given-names>O</given-names></name><name><surname>Borensztein</surname><given-names>P</given-names></name><etal/></person-group><article-title>Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat</article-title><source>J Clin Invest</source><year>1990</year><volume>86</volume><fpage>430</fpage><lpage>443</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI114729">doi:10.1172/JCI114729</ext-link></comment><pub-id pub-id-type="pmid">2166755</pub-id></element-citation></ref><ref id="GFT203C47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Gonz&#x000e1;lez</surname><given-names>JF</given-names></name><name><surname>Mora-Fern&#x000e1;ndez</surname><given-names>C</given-names></name><name><surname>Garcia-P&#x000e9;rez</surname><given-names>J</given-names></name></person-group><article-title>Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis</article-title><source>Semin Dial</source><year>2009</year><volume>22</volume><fpage>37</fpage><lpage>44</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1525-139X.2008.00530.x">doi:10.1111/j.1525-139X.2008.00530.x</ext-link></comment><pub-id pub-id-type="pmid">19250445</pub-id></element-citation></ref><ref id="GFT203C48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanbay</surname><given-names>M</given-names></name><name><surname>Goldsmith</surname><given-names>D</given-names></name><name><surname>Uyar</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Magnesium in chronic kidney disease: challenges and opportunities</article-title><source>Blood Purif</source><year>2010</year><volume>29</volume><fpage>280</fpage><lpage>292</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000276665">doi:10.1159/000276665</ext-link></comment><pub-id pub-id-type="pmid">20090315</pub-id></element-citation></ref><ref id="GFT203C49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laecke</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>Hypomagnesaemia, the kidney and the vessels</article-title><source>Nephrol Dial Transplant</source><year>2012</year><volume>27</volume><fpage>4003</fpage><lpage>4010</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfs126">doi:10.1093/ndt/gfs126</ext-link></comment><pub-id pub-id-type="pmid">22610987</pub-id></element-citation></ref><ref id="GFT203C50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Haese</surname><given-names>PC</given-names></name><name><surname>Couttenye</surname><given-names>MM</given-names></name><name><surname>Lamberts</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients</article-title><source>Clin Chem</source><year>1999</year><volume>45</volume><fpage>1548</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">10471660</pub-id></element-citation></ref></ref-list></back></article>